Vision loss is a real concern for diabetics. According to researchers, diabetics fear blindness more than they do death. The cause for potential vision loss due to diabetes results when blood vessels in the retina leak, and in a more severe stage, there is a profusion of fragile new blood vessels that form in the back of the eye that can leak.

In late-stage clinical trials, ruboxistaurin, an experimental drug developed by Eli Lilly, has proven effective in reducing vision loss caused by the effects of diabetes on the retina by 41 percent. The U.S. Food and Drug Administration has now agreed to review the research data in making a decision on whether to approve ruboxistaurin.

If approved, ruboxistaurin will be sold under the brand name Arxxant. As I understand what I am reading about this drug, it will be the first oral pill designed to slow or prevent vision loss. While the researchers were hoping the drug would slow progression of advanced vision loss, it appeared to be effective only in the early stages of diabetic retinopathy.